DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Chemical Strategy to Translate Genetic/epigenetic Mechanisms to Breast Cancer Therapeutics
Annual rept. 1 Jul 2011-30 Jun 2012
GLADSTONE INSTITUTES IRVINE CA
Pagination or Media Count:
This project is designed to use a molecular signature strategy to develop new therapeutics against metastatic breast cancer. We have recently published this novel pathway-centric technology developed on a prostate cancer model Li et al., 2012b. The goal for this project is to define a panel of genes that are tightly associated with breast cancer transition from initial epithelial morphology to mesenchymal-like cells. This process, known as the EMT transition, has been shown to play a critical role for breast cancer metastasis. Once the panel of EMT-linked is defined on a triple negative breast cancer, the next step is to conduct small molecular screens against such collection of responsive genes. Resulting candidate hits will be characterized on cell and animal models to determine their biological effects in inhibiting breast cancer metastasis to distal organs. This approach is uniquely suited to attack disease pathways in the absence of druggable targets that can be pursued by conventional approaches.
APPROVED FOR PUBLIC RELEASE